Dr. Buchschacher Jr. is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4733 W Sunset Blvd
Los Angeles, CA 90027Phone+1 323-783-4011
Education & Training
- University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 1999 - 2001
- University of California (San Diego) Medical CenterResidency, Internal Medicine, 1995 - 1999
- University of Wisconsin School of Medicine & Public HealthClass of 1994
Certifications & Licensure
- CA State Medical License 1997 - 2025
- WI State Medical License 1997 - 2025
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Publications & Presentations
PubMed
- 138 citationsAbiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer.Noel W Clarke, Andrew J Armstrong, Antoine Thiery-Vuillemin, Mototsugu Oya, Neal Shore
NEJM Evidence. 2022-09-01 - 100 citationsAtezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial.Thomas Powles, Kobe C Yuen, Silke Gillessen, Edward E Kadel 3rd, Dana Rathkopf
Nature Medicine. 2022-01-01 - 147 citationsIpatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.Christopher Sweeney, Sergio Bracarda, Cora N. Sternberg, Kim N. Chi, David Olmos
Lancet. 2021-07-10
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: